PIPELINE PHYSICS - Key Persons
Dr. Gary Summers is President and Founder of Pipeline Physics LLC, a consulting boutique that provides research, education and consulting for project portfolio management (PPM) and the management of pharmaceutical pipelines.
Dr. Summers develops decisions methods that manage uncertainty well. These methods augment the predict-then-act, forecasting approach of decision analysis and portfolio optimization with robust and flexible decision methods. In situations that are only partially understood, contain unknown-unknowns, and more generally, produce surprises, robust, flexible decision methods perform best.
Advances in decision theory are creating this field, and Dr. Summers is pioneering their application to PPM and pharmaceutical pipelines. His research is producing:
A new model of pharmaceutical pipelines, which shows how upstream decisions affect downstream results, especially late-stage attrition.
Feedback for improving the management of pharmaceutical pipelines. Metaphorically, it is evidence-based medicine for PPM and pipeline management.
Simulation technology for studying and teaching decision-making, teaming and PPM. This technology won a Best Paper Award from the Association of Business Simulation and Experiential Learning and is the subject of three US patents.
Robust methods and metrics for evaluating and selecting projects in phase-gate systems and pharmaceutical pipelines.
Dr. Summers received a BA in physics from Washington University, St. Louis, and a MS and a PhD in Industrial Engineering and Management Science from Northwestern University. He was a post-doctoral fellow at Oregon Graduate Institute, which is now part of Oregon Health and Science University, and a visiting research professor at Portland State University.
Job Titles:
- Founder and President of Project & Portfolio Value Creation
Dr. Bayney is the founder and president of Project & Portfolio Value Creation (PPVC). To Pipeline Physics, Dr. Bayney brings more than twenty-three years of experience and comprehensive knowledge of pharmaceutical pipelines.
Domain Expertise: project & portfolio management, risk analysis & risk management, asset valuation, strategic planning, licensing & business development, drug discovery & development.
23-year veteran of the pharmaceutical & biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson.
Dr. Bayney is the founder and president of Project & Portfolio Value Creation (PPVC). To Pipeline Physics, Dr. Bayney brings more than twenty-three years of experience and comprehensive knowledge of pharmaceutical pipelines. His expertise and accomplishments include:
Domain Expertise: project & portfolio management, risk analysis & risk management, asset valuation, strategic planning, licensing & business development, drug discovery & development.
23-year veteran of the pharmaceutical & biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson.
Previous position - Vice President, Portfolio Management & Decision Analysis, Johnson & Johnson Pharmaceutical Research & Development.
19 years training, building, and leading departments in strategic planning, decision analysis, and portfolio management using a capability maturity model (CMM) diagnostic methodology.
2 years as international project manager for marketed cardiovascular drug.
10 years in molecular biology research into gene expression of (a) hepatic drug detoxification systems and (b) amyloid precursor protein in alzheimer's disease.
Faculty member at School of Arts & Sciences and School of Engineering, University of Pennsylvania lecturing in (a) project portfolio management and (b) decision modeling.
Created a unique portfolio management framework - CREOPMTM - that has been applied successfully across several industry sectors and is the basis of his first co-authored book titled Enterprise Project Portfolio Management: Building Competencies For R&D And IT Investment Success, (J. Ross; 2012).
Delivers masterclasses in clinical and CMC risk management, and decision analysis & portfolio management to the R&D and clinical trial management communities in the U.S., EU, and Asia.
BS From the University of East London, MS and PhD from the University of London, MBA from Columbia University, and PMP from the Project Management Institute.